Avantor (NYSE:AVTR – Get Rating) and Seer (NASDAQ:SEER – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for Avantor and Seer, as provided by MarketBeat.com.
Get Avantor alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avantor | 0 | 4 | 10 | 0 | 2.71 |
| Seer | 0 | 2 | 1 | 0 | 2.33 |
Avantor currently has a consensus target price of $33.43, suggesting a potential upside of 67.06%. Seer has a consensus target price of $13.00, suggesting a potential upside of 65.39%. Given Avantor's stronger consensus rating and higher probable upside, equities analysts plainly believe Avantor is more favorable than Seer.
Earnings & Valuation
This table compares Avantor and Seer's top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avantor | $7.39 billion | 1.83 | $572.60 million | $0.93 | 21.52 |
| Seer | $6.62 million | 74.14 | -$71.17 million | ($1.37) | -5.74 |
Avantor has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Avantor has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Institutional and Insider Ownership
81.2% of Avantor shares are owned by institutional investors. Comparatively, 75.9% of Seer shares are owned by institutional investors. 1.6% of Avantor shares are owned by insiders. Comparatively, 18.0% of Seer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Avantor and Seer's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avantor | 8.27% | 27.14% | 7.18% |
| Seer | -695.94% | -17.12% | -16.03% |
Summary
Avantor beats Seer on 11 of the 14 factors compared between the two stocks.
About Avantor
(Get Rating)
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
About Seer
(Get Rating)
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.